Jamie M Orengo - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jamie M Orengo

Showing results (21-30 of 29) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 29 results.

American Journal of Respiratory and Critical Care Medicine|March 2, 2021

Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical TrialMohamed H Shamji, Iesha Singh, Janice A Layhadi, et al.

Science Translational Medicine|December 13, 2023

A therapeutic strategy to target distinct sources of IgE and durably reverse allergyAndre Limnander, Navneet Kaur, Seblewongel Asrat, et al.

Allergy|May 15, 2026

Type-2-Inflammatory-Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 BlockadeJennifer D Hamilton, Manuel A R Ferreira, Wei Keat Lim, et al.

The Journal of Allergy and Clinical Immunology|June 14, 2021

Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 studyPhilippe Gevaert, Jarno De Craemer, Natalie De Ruyck, et al.

Allergy|December 14, 2024

Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II StudySayantani B Sindher, Kari C Nadeau, R Sharon Chinthrajah, et al.

Science Translational Medicine|January 11, 2023

Blocking common γ chain cytokine signaling ameliorates T cell-mediated pathogenesis in disease modelsAudrey Le Floc'h, Kirsten Nagashima, Dylan Birchard, et al.

Allergy|December 14, 2024

Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut AllergyR Sharon Chinthrajah, Sayantani B Sindher, Kari C Nadeau, et al.

Science Translational Medicine|October 29, 2025

The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthmaSeblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan, et al.

Ebiomedicine|August 26, 2022

Diffuse alveolar damage patterns reflect the immunological and molecular heterogeneity in fatal COVID-19Jonas S Erjefält, Natália de Souza Xavier Costa, Jimmie Jönsson, et al.

Pageof 3

Search research articles

Showing results (21-30 of 29) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 29 results.

American Journal of Respiratory and Critical Care Medicine|March 2, 2021

Science Translational Medicine|December 13, 2023

A therapeutic strategy to target distinct sources of IgE and durably reverse allergyAndre Limnander, Navneet Kaur, Seblewongel Asrat, et al.

Allergy|May 15, 2026

Type-2-Inflammatory-Diseases Share Comorbidities, Molecular Signatures, IL4/IL13 Genetics, and Response to IL4/IL13 BlockadeJennifer D Hamilton, Manuel A R Ferreira, Wei Keat Lim, et al.

The Journal of Allergy and Clinical Immunology|June 14, 2021

Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 studyPhilippe Gevaert, Jarno De Craemer, Natalie De Ruyck, et al.

Allergy|December 14, 2024

Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II StudySayantani B Sindher, Kari C Nadeau, R Sharon Chinthrajah, et al.

Science Translational Medicine|January 11, 2023

Blocking common γ chain cytokine signaling ameliorates T cell-mediated pathogenesis in disease modelsAudrey Le Floc'h, Kirsten Nagashima, Dylan Birchard, et al.

Allergy|December 14, 2024

Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut AllergyR Sharon Chinthrajah, Sayantani B Sindher, Kari C Nadeau, et al.

Science Translational Medicine|October 29, 2025

The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthmaSeblewongel Asrat, Wei Keat Lim, Subhashini Srivatsan, et al.

Ebiomedicine|August 26, 2022

Diffuse alveolar damage patterns reflect the immunological and molecular heterogeneity in fatal COVID-19Jonas S Erjefält, Natália de Souza Xavier Costa, Jimmie Jönsson, et al.

Pageof 3